ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
47 announcements with these filters
Metropolis delivered a robust 16% revenue growth, beating prior 12-13% organic guidance. Operating leverage is kicking in, with H1 margins expanding 190 bps despite heavy monsoon headwinds and no price hikes.
Metropolis Healthcare declared an interim dividend of ₹1 per equity share for FY 26-27. The record date is 9 November 2026.
Metropolis Healthcare posted Q2 FY27 revenue up 16% to ₹497 crore and PAT up 43% to ₹75 crore. Board declared a ₹1 per share interim dividend.
Q2 FY27 revenue INR 497 Cr (+16% YoY), EBITDA INR 135 Cr at 27.2% margin, PAT INR 75 Cr (+43%). H1 revenue INR 947 Cr (+16%). Strategy is Metropolis 3.0, focused on tech, science and profitable growth.
Metropolis Healthcare Ltd reported revenue from operations of ₹496.8 Cr (+15.8% YoY) and net profit of ₹75.5 Cr (+42.7% YoY) for Q2 FY27.
Metropolis Healthcare granted 24,060 RSUs and 3,58,920 ESOPs under its 2025 plans, and allotted 65,600 shares under its RSU Plan 2020.
Metropolis Healthcare intimated a board meeting on November 3, 2026 to consider Q2 and half-year unaudited results and possible interim dividend. Trading window is closed October 1 to November 5, 2026.
Metropolis Healthcare Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026. This disclosure provides details on the company's equity share distribution.
Metropolis Healthcare allotted 9,516 equity shares under its RSU Plan, 2020. This issuance follows the exercise of vested stock units by employees.
Metropolis Healthcare filed the quarterly certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Metropolis Healthcare provided a business update for Q2FY27, reporting 15% Y-o-Y revenue growth driven by increased patient and test volumes alongside improved EBITDA margins.
Metropolis Healthcare allotted 66,312 equity shares to employees under its RSU Plan, 2020. This exercise follows the vesting of RSUs previously granted to staff.
Metropolis Healthcare's subsidiary MQSPL will issue shares to Medsource and Dr. Puneet Kumar Nigam for ₹1.26 Crore, diluting MHL's stake to 54.90% through this strategic restructuring.
Franklin Templeton Mutual Fund acquired 7,42,409 Metropolis Healthcare shares via open market, raising its stake to 5.10%. No transaction value was disclosed in the filing.
Metropolis Healthcare transferred its External Quality Assessment Services Division to subsidiary MQSPL for ₹1.25 Crore. The transfer was executed via a slump sale.
Metropolis Healthcare's subsidiary, MQSPL, will issue 10,000 Optionally Convertible Redeemable Preference Shares (OCRPS) to Dr. Puneet Kumar Nigam. Post-conversion, MQSPL will remain a subsidiary.
Metropolis Healthcare held its 26th Annual General Meeting on August 18, 2026. Shareholders reviewed financial statements and confirmed previous interim dividend payments.
Duru Shah Family Trust (promoter group) sold 10,50,000 shares of Metropolis Healthcare Ltd via open market on August 11, 2026.
Metropolis Healthcare reports a strong Q1FY27, beating its own revenue guidance through volume-led growth and aggressive tier-2/3 expansion.
Metropolis Healthcare has delayed the slump sale of its EQAS division to a subsidiary. The completion date is now extended to October 4, 2026.
Metropolis Healthcare reports strong Q1FY27 results with Revenue at INR 450 Cr (up 17% YoY) and EBITDA at INR 113 Cr (up 27% YoY).
Metropolis Healthcare reported Q1FY27 revenue of ₹450 crore and PAT of ₹57 crore, reflecting strong operational performance and volume growth.
Metropolis Healthcare Ltd reported revenue from operations of ₹450.2 Cr (+16.6% YoY) and net profit of ₹56.9 Cr (+25.9% YoY) for Q1 FY27.
Metropolis Healthcare Ltd allotted 18,700 equity shares under its Restrictive Stock Unit Plan 2020. The company also granted 21,880 options under various employee stock schemes.
Metropolis Healthcare Ltd. has scheduled a board meeting on August 04, 2026, to consider and approve its unaudited standalone and consolidated financial results.
Metropolis Healthcare Limited has issued the notice for its 26th Annual General Meeting, scheduled for August 18, 2026, to address financial statements and director re-appointments.
Metropolis Healthcare Limited submitted its Business Responsibility and Sustainability Report for the financial year 2025-26, as required by SEBI (LODR) Regulations.
Metropolis Healthcare has released its Annual Report for FY 2025-26, along with the notice for its 26th AGM to be held on August 18, 2026.
Metropolis Healthcare Ltd has filed its quarterly shareholding pattern statement for the period ended June 30, 2026, as per regulatory requirements.
Metropolis Healthcare allotted equity shares under its Restrictive Stock Unit Plan. The issuance expands employee ownership with a marginal increase in share capital.